SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
Amendment No. 1
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report: November 30, 2005
BioCryst Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter )
| |
|
|
|
|
| Delaware
|
|
000-23186
|
|
62-1413174 |
| (State or other jurisdiction
|
|
(Commission
|
|
(IRS Employer |
| of incorporation)
|
|
File Number)
|
|
Identification #) |
2190 Parkway Lake Drive, Birmingham, Alabama 35244
(Address of Principal Executive Office)
(205) 444-4600
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2 below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
210.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Explanatory Note: This Form 8-K/A amends the Form 8-K filed by BioCryst Pharmaceuticals, Inc. on
November 30, 2005 (file no. 000-23186) (the “Form 8-K”).
TABLE OF CONTENTS
Item 1.01 Entry Into A Material Definitive Agreement.
As disclosed in the Form 8-K, on November 30, 2005, BioCryst Pharmaceuticals, Inc. (the
“Company”) announced that it entered into a Development and License Agreement dated as of
November 29, 2005 (the “Roche Agreement”), with F.Hoffmann-La Roche Ltd and Hoffman-La Roche
Inc. (collectively “Roche”). The Roche Agreement is a collaboration between the Company and
Roche for development of the Company’s clinical compound BCX-4208 for transplantation and
autoimmune diseases.
The Form 8-K included a description of the material terms of the Roche Agreement. A redacted
copy of the Roche Agreement is attached as Exhibit 10.2 to this Form 8-K/A and incorporated
herein by reference.
Item 9.01. Exhibits.
| |
|
|
| Exhibit No. |
|
Description |
| |
10.2
|
|
Development and License Agreement dated as of November 29,
2005, by and between BioCryst Pharmaceuticals, Inc. and
F.Hoffmann-La Roche Ltd and Hoffman-La Roche Inc. (Portions
omitted pursuant to request for confidential treatment.) |